142 related articles for article (PubMed ID: 19808933)
1. MEPE/OF45 protects cells from DNA damage induced killing via stabilizing CHK1.
Liu S; Wang H; Wang X; Lu L; Gao N; Rowe PS; Hu B; Wang Y
Nucleic Acids Res; 2009 Dec; 37(22):7447-54. PubMed ID: 19808933
[TBL] [Abstract][Full Text] [Related]
2. MEPE/OF45 as a new target for sensitizing human tumour cells to DNA damage inducers.
Zhang P; Wang H; Rowe PS; Hu B; Wang Y
Br J Cancer; 2010 Mar; 102(5):862-6. PubMed ID: 20145617
[TBL] [Abstract][Full Text] [Related]
3. A small peptide mimicking the key domain of MEPE/OF45 interacting with CHK1 protects human cells from radiation-induced killing.
Yu X; Wang H; Liu S; Zhang X; Guida P; Hu B; Wang Y
Cell Cycle; 2010 May; 9(10):1981-5. PubMed ID: 20436300
[TBL] [Abstract][Full Text] [Related]
4. Regulation of mRNA expression of matrix extracellular phosphoglycoprotein (MEPE)/ osteoblast/osteocyte factor 45 (OF45) by fibroblast growth factor 2 in cultures of rat bone marrow-derived osteoblastic cells.
Zhang GX; Mizuno M; Tsuji K; Tamura M
Endocrine; 2004 Jun; 24(1):15-24. PubMed ID: 15249699
[TBL] [Abstract][Full Text] [Related]
5. Radiation activated CHK1/MEPE pathway may contribute to microgravity-induced bone density loss.
Zhang X; Wang P; Wang Y
Life Sci Space Res (Amst); 2015 Nov; 7():53-6. PubMed ID: 26553637
[TBL] [Abstract][Full Text] [Related]
6. Retraction of 'MEPE/OF45 protects cells from DNA damage induced killing via stabilizing CHK1'.
Nucleic Acids Res; 2022 Apr; 50(7):4200. PubMed ID: 35357497
[No Abstract] [Full Text] [Related]
7. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass.
Gowen LC; Petersen DN; Mansolf AL; Qi H; Stock JL; Tkalcevic GT; Simmons HA; Crawford DT; Chidsey-Frink KL; Ke HZ; McNeish JD; Brown TA
J Biol Chem; 2003 Jan; 278(3):1998-2007. PubMed ID: 12421822
[TBL] [Abstract][Full Text] [Related]
8. MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21.
MacDougall M; Simmons D; Gu TT; Dong J
Connect Tissue Res; 2002; 43(2-3):320-30. PubMed ID: 12489176
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-376a sensitizes cells following DNA damage by downregulating MEPE expression.
Sheng J; Luo W; Yu F; Gao N; Hu B
Cancer Biother Radiopharm; 2013 Sep; 28(7):523-9. PubMed ID: 23570370
[TBL] [Abstract][Full Text] [Related]
10. Need radioprotection? A MEPE/OF45 mimetic may do the job.
Li CY
Cell Cycle; 2010 Jun; 9(12):2271. PubMed ID: 20581437
[No Abstract] [Full Text] [Related]
11. Enhancement of cellular radiation sensitivity through degradation of Chk1 by the XIAP-XAF1 complex.
Kim KS; Heo JI; Choi KJ; Bae S
Cancer Biol Ther; 2014; 15(12):1622-34. PubMed ID: 25535897
[TBL] [Abstract][Full Text] [Related]
12. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway.
Zhang YW; Otterness DM; Chiang GG; Xie W; Liu YC; Mercurio F; Abraham RT
Mol Cell; 2005 Sep; 19(5):607-18. PubMed ID: 16137618
[TBL] [Abstract][Full Text] [Related]
13. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.
Liu S; Brown TA; Zhou J; Xiao ZS; Awad H; Guilak F; Quarles LD
J Am Soc Nephrol; 2005 Jun; 16(6):1645-53. PubMed ID: 15843468
[TBL] [Abstract][Full Text] [Related]
14. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.
David V; Martin A; Hedge AM; Rowe PS
Endocrinology; 2009 Sep; 150(9):4012-23. PubMed ID: 19520780
[TBL] [Abstract][Full Text] [Related]
15. Matrix extracellular phosphoglycoprotein inhibits phosphate transport.
Marks J; Churchill LJ; Debnam ES; Unwin RJ
J Am Soc Nephrol; 2008 Dec; 19(12):2313-20. PubMed ID: 19005008
[TBL] [Abstract][Full Text] [Related]
16. Wnt3a stimulates Mepe, matrix extracellular phosphoglycoprotein, expression directly by the activation of the canonical Wnt signaling pathway and indirectly through the stimulation of autocrine Bmp-2 expression.
Cho YD; Kim WJ; Yoon WJ; Woo KM; Baek JH; Lee G; Kim GS; Ryoo HM
J Cell Physiol; 2012 Jun; 227(6):2287-96. PubMed ID: 22213482
[TBL] [Abstract][Full Text] [Related]
17. Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts.
Siggelkow H; Schmidt E; Hennies B; Hüfner M
Bone; 2004 Aug; 35(2):570-6. PubMed ID: 15268910
[TBL] [Abstract][Full Text] [Related]
18. In situ localization and in vitro expression of osteoblast/osteocyte factor 45 mRNA during bone cell differentiation.
Igarashi M; Kamiya N; Ito K; Takagi M
Histochem J; 2002 May; 34(5):255-63. PubMed ID: 12588003
[TBL] [Abstract][Full Text] [Related]
19. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.
Addison WN; Nakano Y; Loisel T; Crine P; McKee MD
J Bone Miner Res; 2008 Oct; 23(10):1638-49. PubMed ID: 18597632
[TBL] [Abstract][Full Text] [Related]
20. Active sites of human MEPE-ASARM regulating bone matrix mineralization.
Minamizaki T; Sakurai K; Hayashi I; Toshishige M; Yoshioka H; Kozai K; Yoshiko Y
Mol Cell Endocrinol; 2020 Nov; 517():110931. PubMed ID: 32712387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
